drugset / Trial / NCT05807776
Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase II prospective study to evaluate the safety and efficacy of Tislelizumab monotherapy or combined with lenvatinib as neoadjuvant therapy for resectable hepatocellular carcinoma.
Timeline
- Start
- 2023-04-24
- Primary completion
- 2024-07-24
- Completion
- 2025-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |